The recent discovery that genetically modified a cells can regenerate and convert into b-like cells in vivo holds great promise for diabetes research. However, to eventually translate these findings to human, it is crucial to discover compounds with similar activities. Herein, we report the identification of GABA as an inducer of a-to-b-like cell conversion in vivo. This conversion induces a cell replacement mechanisms through the mobilization of duct-lining precursor cells that adopt an a cell identity prior to being converted into b-like cells, solely upon sustained GABA exposure. Importantly, these neo-generated b-like cells are functional and can repeatedly reverse chemically induced diabetes in vivo. Similarly, the treatment of transplanted human islets with GABA results in a loss of a cells and a concomitant increase in b-like cell counts, suggestive of a-to-b-like cell conversion processes also in humans. This newly discovered GABA-induced a cell-mediated b-like cell neogenesis could therefore represent an unprecedented hope toward improved therapies for diabetes.
INTRODUCTION
The mature pancreas includes three main cell subtypes: acinar, duct, and endocrine cells. Acinar cells produce and secrete digestive enzymes, which are routed to the intestine by a branched ductal network. Endocrine cells are involved in regulating nutrient metabolism and glucose homeostasis. Specifically, these are organized into cell clusters termed islets of Langerhans that are composed of five cell subtypes, each secreting a specific endocrine hormone: a-, b-, d-, ε-, and PPcells producing glucagon, insulin, somatostatin, ghrelin, and pancreatic polypeptide (PP), respectively (Collombat et al., 2006) . Both type 1 and 2 diabetes (T1D and T2D, respectively) ultimately result in pancreatic b cell loss and chronic hyperglycemia (Cnop et al., 2005) . Importantly, despite the most recent advances in diabetes care, patients suffering from T1D still display, on average, a shortened life expectancy and a worsened quality of life as compared to healthy individuals. Aiming to develop alternative treatments, the replacement of lost b cells using different cell sources, such as stem, precursor, or differentiated cells, represents a promising strategy. However, despite major advances in mimicking embryonic b cell development in vitro (Pagliuca et al., 2014; Rezania et al., 2014) , a deeper understanding of the genetic program underlying human b cell genesis is still required to eventually generate fully differentiated b cells (Nair and Hebrok, 2015) . Toward this goal, and using the mouse as a model, a number of studies have demonstrated that during pancreas morphogenesis, several transcription factors are successively involved in the specification of pancreatic precursors toward the different endocrine cell fates. Among these, Pdx1 is required for pancreatic epithelium determination (Pan and Wright, 2011) whereas Ngn3 specifies the endocrine cell lineage (Gradwohl et al., 2000) . Following Ngn3 induction, a complex network of transcription factors, including Arx and Pax4, drives endocrine precursor cells toward the different endocrine cell fates. These two factors were found to mutually inhibit each other's transcription and to display antagonistic activities for proper endocrine cell lineage allocation (Collombat et al., 2005) . Indeed, Pax4 promotes the b and d cell lineages, whereas Arx is involved in specifying the a cell fate (Collombat et al., 2003 (Collombat et al., , 2005 (Collombat et al., , 2007 Sosa-Pineda et al., 1997) . Importantly, it was previously demonstrated that embryonic glucagon-producing cells can continuously regenerate and convert into insulin-producing b-like cells through the sole ectopic expression of Pax4 (Collombat et al., 2009) . It was subsequently shown that the misexpression of Pax4 in mouse adult a cells also induces their neogenesis and conversion into b-like cells, these being functional and allowing the reversion of multiple cycles of chemically induced hyperglycemia (Al-Hasani et al., 2013) . Finally, the downregulation of Arx activities in glucagon + cells was recently found to represent the main trigger for a-to-b-like cell conversion . The regenerative capacity of glucagon-producing cells and their potential to convert into b-like cells are of great interest in the context of T1D research. However, the aforementioned transgenic approaches cannot be translated to diabetes treatment in humans. We therefore performed a number of screens aiming to identify small molecules/chemical compounds mimicking the effects of the ectopic expression of Pax4/inhibition of Arx in a cells. Here, we report the identification of g-aminobutyric acid (GABA) as an a-to-b-like cell inducer. Interestingly, previous studies have suggested a role for GABA in the endocrine pancreas and in diabetes mellitus. GABA, synthesized from glutamate by glutamic acid decarboxylase (GAD) in b cells, is an extracellular signaling molecule acting on the pancreatic islets (Adeghate and Ponery, 2002) . Once released, GABA is thought to serve as a functional regulator of pancreatic hormone secretion or as a fast-acting paracrine signaling molecule for the communication between b cells and other islet cells (Franklin and Wollheim, 2004 ). In addition, other studies have demonstrated that GABA participates in maintaining the b cell mass and in protecting b cells from apoptosis in vitro (Soltani et al., 2011) . Of note, a putative b cell proliferation was suggested upon short-term GABA treatment but, in the absence of lineage tracing, this remains to be ascertained (Soltani et al., 2011) . Here, using lineage tracing, we provide evidence that long-term GABA treatment eventually induces the conversion of glucagon-expressing a cells into functional insulin-producing b-like cells. Interestingly, this a-to-b-like cell conversion leads to the reactivation of developmental processes resulting in a compensatory a cell neogenesis. Upon sustained GABA administration, these newly generated a cells are again converted into b-like cells, such cycle of neogenesis and conversion eventually leading to b-like cell hyperplasia. Importantly, upon GABA administration, the entire b cell mass can be regenerated at least twice following two cycles of streptozotocinmediated b cell ablation. Lastly, we provide in vitro and ex vivo evidence that human a cells can also be converted into b-like cells upon maintained GABA exposure, such results opening the way for clinical trials with GABA or GABA-like compounds.
RESULTS
Long-Term Treatment of Wild-Type Mice with GABA Induces a Significant b-like Cell Hyperplasia Through the generation and analysis of Glu-rtTA::TetO-Pax4 double transgenic animals (harboring transgenes encompassing the rat glucagon promoter upstream of the reverse tetracycline-dependent transactivator and the Tet operator upstream of Pax4 cDNA), we previously demonstrated that the misexpression of Pax4 triggered in adult a cells induces their continuous neogenesis and subsequent conversion into b-like cells (Al-Hasani et al., 2013) . Subsequent work provided evidence that the downregulation of Arx expression in a cells is in fact the main trigger of their conversion into b-like cells . Aiming to gain further insight into the molecular mechanisms underlying these processes, we performed a number of screens (Li et al., 2016, [this issue of Cell] ), including transcriptomic analyses using islets isolated from Glu-rtTA::TetO-Pax4 animals treated for increasing durations with doxycycline compared to salinetreated controls. Our results, sorted by fold change, outlined strong alterations in the expression of several genes involved in GABA signaling (unpublished data; Figure S1A ). For instance, when comparing 3-month doxycycline-treated versus saline-treated pancreata, the expression of the b cell-specific GABA B receptor was increased >15 times. Similarly, a 7-fold augmentation in GABA A receptor transcripts, a 10.5-fold rise in GAD transcripts, and an 8.5-fold increase in the expression of the GABA A receptor target, gephyrin, were observed ( Figure S1A ).
Such alterations being suggestive of an activation of GABA pathways, we initially assayed its short-term role in vitro using the a-TC1-6 a cell line (Hamaguchi and Leiter, 1990) . These cells were treated (or not) daily with concentrations of GABA ranging from 5 mM to 1 mM and kept in culture for up to 6 weeks ( Figure S1B ). Insulin expression appeared unchanged upon GABA treatment (data not shown). However, the a-TC1-6 cell line, derived from an induced adenoma and passaged over time, may not fully recapitulate the endogenous inherent a cell plasticity. We therefore focused on Arx expression whose downregulation triggers a-to-b-like cell conversion in mice . Interestingly, even at low GABA concentrations, a comparative analysis of Arx expression by qRT-PCR outlined a rapid decrease in Arx transcript contents, with a maximum of 31% as compared to controls ( Figure S1B ). These encouraging results prompted us to test GABA activities in vivo by combining long-term GABA administration and immunohistochemical analyses. Thus, 2.5-to 10-monthold wild-type (WT) mice were subjected to a 1-to 6-month (1-6 m) GABA treatment (250 mg/kg) by daily intraperitoneal injections. These animals were viable, healthy, and fertile, their lifespan, weight, and basal glycemia remaining within normal range ( Figure 1A and data not shown). Importantly, the examination of GABA-treated pancreata ( Figures 1C, 1D , 1F, 1G, 1I, and 1J) outlined a dramatic islet hypertrophy mostly resulting from a massive increase in the insulin + cell numbers (while the size of insulin + cells was found unchanged; data not shown), as compared to control mice ( Figures 1B, 1E, and 1H ). This insulin + cell hyperplasia further increased with the duration of GABA treatment, aging not seeming to impact these processes ( Figures 1A and 1K) . Furthermore, the number of islets in GABA-treated mice was found to be doubled compared to controls, independently of the duration of GABA exposure ( Figures 1A and 1K ). In addition, GABA-treated mice also displayed higher numbers of glucagon + and somatostatin + cells as compared to their non-treated counterparts ( Figures 1D-1K ). It is also important to note the atypical positioning of these non-b cells within the islets, most of these being detected in clusters close to ducts ( Figures 1F, 1G , 1I, and 1J) and not uniformly distributed within the islet mantle zone, as seen in controls ( Figures 1E and 1H) . Additional experiments using increasing concentrations of GABA (1-5 mg/kg) demonstrated a dose-dependent augmentation in the number of in- (A) Wild-type mice were treated with GABA at the indicated ages and for the specified durations. Note that while life expectancy and basal glycemia are within normal ranges, an increase in islet count and size is observed in all conditions, such increases being dependent on the duration of treatment. Interestingly, aging does not impact on these neogenesis processes. Indeed, 10-month-old and 2.5-month-old animals treated with GABA for 3 months exhibit a similar augmentation in islet size and number. ***p < 0.001, **p < 0.01, *p < 0.05 using a MannWhitney test; all data depicted as mean ± SEM (n R 6). (B-J) Immunohistochemical staining using different hormone combinations of pancreatic sections from controls (B, E, and H) and GABA-treated (C, D, F, G, I, and J) animals. A massive increase in islet size and numbers is observed. S2J ). In all subsequent experiments, we used 250 mg/kg of GABA, corresponding to the minimal concentration that caused a significant increase in insulin + cell numbers. In an effort to potentially discriminate newly formed from pre-existing insulin + cells in GABA-treated pancreata, we assayed the expression of several endocrine cell marker genes ( Figures 2C, 2D , 2G, 2H, 2K, 2L, 2O, 2P, 2S, 2T, 2W, 2X, 2Z1, 2Z2, 2Z5, and 2Z6) compared to saline-treated controls (Figures 2A, 2B , 2E, 2F, 2I, 2J, 2M, 2N, 2Q, 2R, 2U, 2V, 2Y, 2Z, 2Z3, and 2Z4) by immunohistochemistry. These analyses revealed that all insulin + cells in GABAtreated islets uniformly expressed the bona fide b cell markers, such as the prohormone convertase 1/3 (PC1/3) (Figures 2A-2D ), the transcription factors Nkx6.1 ( Figures 2E-2H ), and Pdx1 ( Figures 2I-2L ), the b cell-specific glucose transporter Glut 2 ( Figure 2M -P), as well as the pan-endocrine markers Pax6 ( Figures 2Q-2T ) and NeuroD1 ( Figures 2U-2X ). These cells also lacked the non-b cell labels, such as glucagon ( Figures  1E-1J ) and somatostatin ( Figures 1H-1J ). Interestingly, as expected from the in vitro data ( Figure S1B ), a number of glucagon + cells were found negative for were analyzed by electron microscopy following insulin immunogold labeling: a thorough examination of more than 200 photographs per pancreas (n = 3) indicated that all cells displaying a b cell ultrastructure expressed insulin and that all insulin-labeled cells exhibited a b cell phenotype in GABA-treated pancreata ( Figures S3A-S3D ). Interestingly, functional tests performed in GABA 3 m animals confirmed improved glucose tolerance, these animals demonstrating a lower peak in glycemia, a faster return to normoglycemia, and a 3.1-fold increase in insulin secretion as compared to saline-treated animals ( Figure S3E and inset), all suggestive of an augmented functional b-like cell mass. Nevertheless, despite a significant b-like cell hyperplasia, GABA treatment did not cause any resistance to insulin as outlined by insulin tolerance tests carried out in GABA 6 m animals ( Figure S3F ). Taken together, our data suggest that long-term GABA administration induces a downregulation of Arx expression/ ectopic expression of Pax4 in a cells and a concomitant increase in b-like cell mass. Furthermore, daily administration of GABA to WT mice leads to islet neogenesis accompanied by progressive islet hypertrophy, the latter resulting from hyperplasia of functional b-like cells, as well as an increase in glucagon + and somatostatin + cell numbers.
GABA Induces the Conversion of Glucagon-Expressing Cells into b-like Cells
To determine the origin of the hyperplastic endocrine cells observed in GABA-treated pancreata, further immunohistochemical analyses were performed. In very rare instances, we observed cells co-expressing both insulin and glucagon (Figures 3A and 3B) . Aiming to determine whether these may correspond to cells transitioning from an a-to a b-like cell phenotype, we treated Glu-Cre::ROSA mice (harboring the following transgenes: the rat glucagon promoter upstream of the phage P1 Cre recombinase [Herrera, 2000] and the Rosa26 promoter upstream of a loxP-Stop-loxP-b-galactosidase cassette (Soriano, 1999] ) with GABA (or saline) for 2 months. Using X-gal staining to visualize b-galactosidase activity, we followed the outcome of cells having expressed or still expressing glucagon. b-gal + cells were detected solely in the mantle zone of islets from control mice treated with saline where glucagon-expressing cells are located ( Figures 3C-3E ). Importantly, in GABA-treated animals, b-gal + cells were located not only in the islet mantle zone but 1G , 1I-1K, and S2J). In addition, the apoptosis rate was similar in GABA-versus saline-treated animals (data not shown). Together, these observations suggest a continued neogenesis of glucagon + cells upon GABA treatment. Therefore, long-term (10 days) 5-bromo-2 0 -deoxyuridine (BrdU) labeling was used to detect cells undergoing or having undergone replication. As expected, very few BrdU-labeled cells (mostly insulin-expressing cells) were noted in control mice ( Figures 4A, 4D , 4G, and 4J). However, in GABA-treated animals, a significant 7.0-fold ± 0.6-fold increase in the number of BrdU + cells was observed ( Figures   4A-4C) , mainly within the epithelial cells in and near the lining of ducts and, to a lesser extent, within the endocrine compartment ( Figures 4B, 4C , 4E, 4F, 4H, 4I, 4K, and 4L). In addition, long-term GABA-treated mice often demonstrated a thickening of the ductal lining in a cell nuclei-dense area reminiscent of mesenchyme (Figures S5B and S5C compared to S5A). Indeed, closer examination revealed that most of these cells re-expressed the canonical mesenchymal marker, vimentin ( Figure S5C ). Similarly, Snai2 + cells were also detected at the same loci in the pancreata of GABA-treated animals ( Figures S5D-S5F ). Note that these markers were only expressed in scattered cells of control mice ( Figures S5A and S5D and data not shown). Because vimentin and Snai2 are transcriptional regulators/hallmarks of the developmental epithelium to mesenchymal transition (EMT), these data suggest that the neo-generated endocrine cells undergo EMT as observed during embryogenesis (Habener et al., 2005) .
Ngn3 Re-expression Is Required for Endocrine Cell Neogenesis upon GABA Administration To further investigate a putative reactivation of endocrine developmental processes upon daily GABA administration, we analyzed the expression of a number of developmental A 10-day BrdU pulse was performed in 2-monthold saline 2 m (A, D, G, and J) and GABA 2 m (B, C, E, F, H, I, K, and L) animals. While few proliferating cells were detected in controls, seven times more proliferating cells were observed in GABA-treated animals (B and C versus A; n = 4, p < 0.001). Interestingly, this increase in proliferating cell numbers was preferentially detected in the pancreatic ductal lining and epithelium, adjacent to islets (B, C, E, F, H, I, K, and L). Note also the presence of insulin-(B and C), glucagon-(E and F), or somatostatin-(H and I) expressing cells labeled with BrdU, suggesting that such cells have proliferated prior to hormone expression. For the purpose of clarity, the ductal lumen is outlined with dashed white lines, whereas the islets are outlined with dashed yellow lines.
marker genes involved in endocrine cell genesis. Interestingly, we observed a reactivation of the expression of the pro-endocrine gene Ngn3 in cells located within the ductal compartment of GABA-treated pancreata (Figures 5B and 5C), while almost no expression of Ngn3 could be detected in control mice ( Figure 5A ). Lineage tracing experiments were subsequently performed to determine the putative contribution of these Ngn3-re-expressing cells to the supplementary endocrine cell mass. We used Ngn3-CreER TM mice (harboring a transgene composed of the Ngn3 promoter upstream of the phage P1 Cre recombinase fused to a mutant estrogen receptor) (Gu et al., 2002) crossed with the aforementioned ROSA animals. In GABA-and Tam-treated Ngn3-CreER::ROSA transgenic mice, a large number of b-Gal-labeled cells were observed near the ductal lining and, most importantly, within the islets (Figures 5E-5J ), while controls appeared negative for b-galactosidase ( Figure 5D ). To further confirm the role of Ngn3 in the endocrine cell hyperplasia observed in GABAtreated animals, Ngn3 expression was inhibited in vivo by a knock-down approach. Following 2 days of GABA treatment, 2-month-old WT animals were injected, via the pancreatic duct, with GFP-encoding lentiviruses producing either a small hairpin RNA (shRNA) targeting Ngn3 transcripts (previously found to induce a 45% decrease in Ngn3 transcript contents) (Al-Hasani et al., 2013; Collombat et al., 2009; Xu et al., 2008) or a scrambled shRNA. Subsequently, the animals were treated daily with GABA and examined 2 months later. While GABA-treated scrambled-infected pancreata displayed hypertrophic islets ( Figures 5K, S5G , and S5H), GABA-treated Ngn3 knock-down pancreata exhibited a 40.5% reduction in islet overgrowth and 69% decrease in islet counts ( Figures 5L,  5M , S5G, and S5H), indicating that Ngn3 re-expression is required for GABA-mediated endocrine cell neogenesis in adult mice. Importantly, we observed an accumulation of mesenchyme-like cells surrounding ducts in Ngn3 knockdown mice ( Figures 5L-5P) , suggestive of endocrine cell neogenesis that was stopped at the mesenchymal stage. Indeed, such cells were found to widely express vimentin ( Figures 5N  and 5O ) or Snai2 ( Figure 5P ). Altogether, our data suggest that long-term GABA treatment eventually induces the reawakening of the Ngn3-controlled endocrine developmental program, such cells undergoing EMT prior to the acquisition of an endocrine cell identity. were functionally equivalent to endogenous b cells, 2-monthold WT animals were injected with a high dose of streptozotocin (STZ) to obliterate the pancreatic b cell mass. Once these animals were overtly diabetic, with a glycemia of 300 mg/dL, they were treated daily with GABA or saline (controls). While saline-treated control mice saw their glycemia increase further and died from extreme hyperglycemia, a steady recovery was (K-P) After 2 days of GABA treatment, 2-month-old WT mice were infected using GFP-encoding lentiviruses producing either a shRNA targeting Ngn3 transcripts or a scrambled shRNA. After infection, the animals were injected daily with GABA for 2 months before being sacrificed for examination. Importantly, while scrambled-infected pancreata display a GABA-mediated increase in islet size and b-like cell counts (K), Ngn3 knock-down pancreata do not exhibit such GABA-induced islet hypertrophy or b-like cell hyperplasia (L and M), demonstrating the requirement of Ngn3 reexpression for endocrine cell neogenesis. Note the massive accumulation of cells around ducts upon Ngn3 knock-down, such cells expressing the EMT labels Vimentin (N and O) or Snai2 (P), suggesting that, in the absence of Ngn3 reexpression, cells are neo-generated upon GABA treatment but fail to acquire an endocrine cell identity and remain in a mesenchymal state. For the purpose of clarity, dashed lines are used to surround the ductal lumen (in white), the islets (in yellow), and the ductal thickening (in green). See also Figure S5 . observed (following a transitory peak in glycemia) in their GABAtreated counterparts ( Figure 6A ). Quantitative immunohistochemical analyses were performed on sections of saline-treated ( Figures 6B and 6C ) and GABA-treated ( Figures 6D-6F ) pancreata isolated 5-85 days post STZ administration. While STZ treatment induced a loss of insulin-producing cells in all conditions (above 96%; Figure 6C ), animals that received GABA displayed a progressive regeneration of their b-like cell mass ( Figures 6D-6F ), resulting in reconstituted islets 70-95 days following b cell ablation. It is worth noting that weight (data not shown) and glycemia were normal in the surviving animals that displayed an extended lifespan compared to controls ( Figure 6A ). The glucose responsiveness of these surviving GABA-treated mice was examined 4.5 months post b cell ablation, that is, following regeneration and additional neogenesis of insulin + cells. Upon challenge with a high dose of glucose, these animals exhibited an improved response with a lower raise in glycemia and a faster return to euglycemia as compared to controls (Figure S6A ). Accordingly, a 2.1-fold increase in maximal insulin secretion, reflecting the augmented content of b-like cells, was observed in GABA-treated mice as compared to saline-administered animals ( Figure S6A and inset). Aiming to further confirm the origin of neo-generated b-like cells, similar b cell ablation experiments were performed in Glu-Cre::ROSA mice allowing a cell lineage tracing. Importantly, using both X-Gal staining and immunohistochemical analyses ( Figures 6G-6J) , the vast majority of newly formed insulin-producing cells were found to be labeled with b-galactosidase (permanently marking cells that once expressed glucagon), demonstrating that most of the regenerated b-like cells passed through a glucagon-expressing transitional phase. Accordingly, the repetition of this b cell ablation procedure in presence of GABA and of an antagonist of the a cell-specific GABA A receptor, SR-95531 (Jin et al., 2013) , prevented the recovery from the lethal hyperglycemia, indicating that GABA mainly acts on a cells via the GABA A receptor ( Figure S6B compared to 6A). It is important to mention that mouse GABA A receptors are indeed expressed in mouse a cells (Bailey et al., 2007) A) Two-month-old WT mice were subjected to high dose streptozotocin (STZ) treatment to ablate b cells and then treated with GABA (or saline) once they were overtly diabetic (glycemia R300 mg/dL). While saline-treated animals died due to severe diabetes, their GABA-treated counterparts, following a peak in glycemia, saw a progressive normalization of their blood glucose levels. (K) WT animals were subjected to a first round of b cell ablation and treated with GABA for 2.7 months to regenerate their b cell mass. GABA administration was subsequently halted for 1 month prior to a second round of STZ-mediated b cell ablation. Half of the animals were treated with GABA daily once their glycemia reached 300 mg/dL, the other half with saline. Importantly, while saline-treated animals died due to severe hyperglycemia, their GABA-treated counterparts survived and eventually saw a normalization of their glycemia. This indicates that a functional b cell mass can be reconstituted at least two times solely upon sustained GABA exposure. All data depicted as mean ± SEM in (A-F) and (K). See also Figure S6 .
Gabre, <0.1; other GABA A subunits, < 0.1; G. Rutter, personal communication). To determine whether GABA could induce more than one cycle of b cell regeneration, mice that went through a first round of b cell ablation and b-like cell regeneration were subjected to a second round of streptozotocin treatment (1 month after stopping GABA treatment). These mice were then administered GABA (or saline) when their glycemia reached 300 mg/dL. Importantly, and as observed previously, while saline-treated mice (survivors of a first ablation round) eventually died from severe hyperglycemia, their GABA-treated counterparts saw, following a transitory peak, a normalization of their blood glucose levels resulting again in an extended lifespan ( Figure 6K ). Taken together, these results demonstrate that GABA treatment counteracts the consequences of chemically induced diabetes, even when the animals are severely diabetic. Importantly, GABA administration can induce at least two cycles of complete b cell mass neogenesis by virtue of regenerating a cells. These findings also provide evidence that the arrest of GABA treatment halts these a cellmediated b-like cell neogenesis processes, indicating that these can be tightly controlled.
GABA Induces the Loss of Human Glucagon + Cells to the Profit of b-like Cells
The aforementioned studies established that GABA administration induces the neogenesis and conversion of a cells into functional b-like cells in mice. However, whether the same applies to other species remained to be tested. Similarly, whether GABA could protect b cells from apoptosis (in addition to inducing their neogenesis) remained to be determined. To address these issues, we first analyzed the effects of cytokine-induced apoptosis (using interleukin-1b and interferon g [IFNg]) on GABA-treated rat INS-1E b cells and on primary fluorescence-activated cell sorting (FACS)-purified rat b cells. In both instances, the apoptosis rates were similar ( Figures S7A and S7B ), indicating that GABA does not prevent cytokine-induced apoptosis. Subsequently, we determined whether FACS-sorted cultured rat a cells could be reprogrammed into insulin-producing cells upon 14 days of GABA treatment ( Figures S7C-S7M) . Interestingly, we observed a GABA dose-dependent decrease in glucagon + cell content (albeit not significant) and a significant diminution in Arx transcript contents ( Figures S7K and S7L ). Concomitantly, a significant increase in the number of insulin + cell numbers was outlined ( Figure S7M ). Additional analyses demonstrated no effect of GABA treatment on the proliferation of FACSsorted a or b cells ( Figure S7K , bottom, and data not shown). Thus, despite the lack of lineage tracing, these data strongly suggest a conversion of a cells into insulin + cells. Unfortunately, the duration of GABA exposure could not be extended beyond 14 days, which corresponds to the maximal duration of viability of primary rat a cells under the present culture conditions. Aiming to determine whether human a cells could also be converted into insulin + cells in vitro, we first used 3D culture of human islets (Kerr-Conte et al., 1996) . Importantly, following 14 days of culture in presence of GABA, we observed a significant 37% diminution in the glucagon + cell counts and a concomitant 24% increase in the insulin + cell numbers, as compared to saline-supplemented islet cultures ( Figure 7A ). These results being suggestive of a-to-b-like cell conversion in human, the reprogramming process was investigated in human islet xenografts. Thus, 500 human islet equivalents were transplanted under the kidney capsule of immunodeficient mice that were subsequently treated daily with GABA (or saline) for 1 month before being sacrificed. A close examination of the transplants indicated a 1.21-fold increase in the total endocrine cell count (chromogranin A + cells) and similar 1.19-fold augmentation in the (a+b) cell counts when comparing GABA-treated animals versus saline-administered counterparts ( Figures 7B-7F) . Importantly, upon GABA administration, the percentage of glucagon + cells decreased 3.8-fold while the percentage of b cells increased 1.4-fold ( Figure 7F ). Despite the present lack of reliable methods for human a cell lineage tracing, these results suggest a conversion of human a cells into insulin-producing cells upon GABA exposure, thereby opening new and promising avenues in the context of diabetes research.
DISCUSSION
Here, we report an unsuspected role of GABA in inducing a continuous conversion of a cells into b-like cells, accompanied by a cell regeneration. Prolonged GABA exposure results in a significant increase in islet size and number due to a b-like cell hyperplasia. This hyperplasia closely correlates with the dose and duration of GABA treatment. Specifically, our results suggest that GABA induces the conversion of a cells into b-like cells through the downregulation of Arx expression, GABA acting via the GABA A receptor located on a cells. This triggers a cell replacement mechanisms involving the mobilization of ductal precursor cells that re-enact the endocrine differentiation program as seen during pancreas development, such a cells being subsequently converted into b-like cells upon sustained GABA exposure. Importantly, the regenerated b-like cells are functional and can repeatedly reverse the consequences of chemically induced b cell ablation, even in severely diabetic animals. As important is the demonstration that the treatment of transplanted human islets with GABA results in a decrease in a cell numbers accompanied by a concomitant increase in the b-like cell counts, suggestive of an a-to-b-like cell conversion capacity in humans. These findings could therefore pave the way toward targeted therapies to restore b cell mass in types 1 and 2 diabetes, both conditions eventually resulting in the loss of b cells. Our analyses reveal that long-term GABA treatment results in a significant, but controllable, increase in insulin-producing cell numbers. Such insulin + cell hyperplasia progresses with the dose and duration of GABA treatment. Interestingly, this insulin + cell hyperplasia does not lead to insulin resistance or augmented circulating insulin levels, such results being in line with previous observations indicating that an increased b cell mass does not impair glucose homeostasis (Rahier et al., 2008; Topp et al., 1998) . In addition, our findings indicate that aging does not impact GABA-mediated insulin + cell neogenesis, as 10-month-old animals respond in a similar fashion to their 2.5-month-old counterparts. Interestingly, an increase in islet number is observed under all conditions tested. However, it appears to plateau at approximately twice the number of islets found in control pancreata. This suggests that GABA can also trigger islet neogenesis but these processes appear to be limited. Gaining further insight into the molecular mechanisms controlling this limitation and determining ways to overcome it would be of obvious interest in the context of b cell regeneration research. Combining lineage tracing, electron microscopy, immunohistochemical analyses, and functional tests, we demonstrate that a cells can be converted into cells displaying most features of b cells upon GABA treatment (Movie S1). While these cells appear to display a b cell phenotype, further work would be required to ascertain whether they are true b cells. Additional analyses indicate that GABA mostly acts via the GABA A receptor located on a cells to eventually induces a downregulation of Arx expression/ectopic expression of Pax4 and thereby promote their conversion into b-like cells (Al-Hasani et al., 2013; Courtney et al., 2013) . It is worth noticing that Artemisinins also appear to elicit a similar a-to-b-like cell conversion by targeting gephyrin and increasing GABA signaling (Li et al., 2016) . In GABA-treated animals, the continued detection of glucagon + cells suggests a cycle involving their replacement and subsequent conversion into b-like cells. Indeed, the monitoring of GABA-treated animals over time outlines increasing numbers of insulin + cells that went through a phase of glucagon expression (as assayed using a cell lineage tracing), thereby confirming the notion of a cell neogenesis/replacement and subsequent conversion into b-like cells. Further work demonstrated the mobilization of epithelial cells located near the ductal lining/epithelium that can adopt an endocrine cell identity through the re-enactment of the Ngn3-mediated endocrine cell differentiation program normally solely active during embryonic development (Movie S1). Such processes are most likely triggered in order to compensate for the loss of a cells (converted into b-like cells upon GABA exposure) and the subsequent glucagon shortage, as previously shown in different models, such as the a cell-specific misexpression of Pax4 (Collombat et al., 2009; Courtney et al., 2013) , the a cell-specific Arx deficiency , or in models of altered glucagon signaling (Furuta et al., 1997; Gelling et al., 2003; Longuet et al., 2013 ). While we demonstrate that prolonged GABA administration eventually induces ductal cells to adopt an endocrine cell identity, it remains to be determined whether this capability corresponds to an inherent feature of all ductal cells or to the mobilization of a specific ductal subpopulation.
Previous reports have suggested a putative role of GABA in inducing b cell proliferation but showed no lineage tracing (Soltani et al., 2011) . In addition, much shorter durations of treatment were used compared to our current report. Our results partly support these findings as we observed that a number of insulin + cells incorporated the nucleotide analog BrdU upon GABA exposure. However, such GABA-induced insulin + cell proliferation does not appear to represent the main mechanism underlying GABA activities upon longer exposure. Indeed, our analyses demonstrate that regenerating a cells represent the main source of newly formed b-like cells. This is further evidenced following b cell ablation in animals allowing a cell lineage tracing: most regenerated b-like cells clearly display an a cell ontogeny.
The demonstration that neo-generated b cells can functionally replace all endogenous b cells at least twice following in vivo chemical ablation is of importance for type 1 and 2 diabetes research, both conditions eventually resulting in loss or decrease of b cells. As mentioned above, GABA was hitherto thought to induce b cell proliferation. While this feature is of interest, a putative application to type 1 diabetic patients would not have been possible due to the loss/lack of pre-existing b cells. However, the present demonstration that, upon long-term GABA administration, regenerating a cells can be used to replenish the b cell mass appears extremely appealing. Similarly, the finding that exposure to GABA could potentially turn human a cells into b-like cells is also exciting. Although the results obtained by transplanting human islets into immunodeficient mice are suggestive, the definitive demonstration of such human a-to-b-like cell conversion will await the development of a cell lineage tracing system allowing the labeling of human a cells and the monitoring of their outcome. Another limitation to these transplantation experiments is the lack/very small number of functional human ductal cells to determine whether these would contribute to the a cell-mediated b-like cell neogenesis.
Should one consider a putative application of these findings to type 1 diabetic patients, one would need to take into account the autoimmune nature of this condition. Indeed, putatively regenerated b-like cells could be targeted by the immune system, which retains memory of b cell antigens. Four possibilities could be envisaged to alleviate this issue. First, GABA could promote the neogenesis and conversion of a cells into b-like cells, the latter retaining some a cell features rendering them ''immune/ more resistant'' to an autoimmune attack. In line with this possibility, we have recently shown that a cells are more resistant than b cells to apoptosis induced by both ''diabetogenic'' viruses (Marroqui et al., 2015b) and metabolic stress . Second, b-like cell regeneration could be faster than the autoimmune-mediated b cell loss. Indeed, it has been shown that type 1 diabetes is a slow progressing condition, as outlined by the progressive decline in insulin secretion in antibody-positive individuals, long before the development of overt diabetes (Cnop et al., 2005) . Third, GABA could potentially harbor some immune-protective activities as previously suggested (Soltani et al., 2011) . Fourth, and in line with the prevailing view that preventive or curative therapies for T1D must be multifactorial (Lord and Greenbaum, 2015) , GABA therapy could be coupled to a mild immunomodulatory approach, aiming to both restore b cell mass and to tolerize the immune system to these neoformed b cells. Clearly, further work is necessary to test these hypotheses, but these paths of research could lead to exciting new findings.
Taken together, our analyses of long-term GABA administration demonstrate that (1) GABA can induce a controllable a cell-mediated b-like cell neogenesis through the downregulation of Arx expression in a cells; (2) the newly formed b-like cells are functional; (3) regenerating a cells exhibit a ductal ontogeny and are generated by reactivation of endocrine developmental processes; (4) the complete b cell mass can be replaced at least twice; and (5) human and rat a cells could potentially be converted into b-like cells. Based on these findings and on the fact that GABA does not cross the blood-brain barrier (Kuriyama and Sze, 1971) , we suggest that long-term GABA treatment could represent a very promising approach as a novel therapy to restore the b cell mass in diabetic patients.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Please contact Patrick Collombat (collombat@unice.fr) for reagents and resources generated in this study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS Animal Maintenance and Manipulations
Mouse protocols were reviewed and approved by Institutional Ethical committee (Ciepal-Azur) at the university of Nice and all colonies were maintained following European animal research guidelines. Male Wistar rats (Charles River Laboratories, L'Arbresle Cedex, France) were housed and used according to the guidelines of the Belgian Regulations for Animal Care, with the approval by the local Ethical Committee. Linage tracing experiments were undertaken by crossing Glucagon-Cre (Herrera, 2000) and Ngn3-CreER (Gu et al., 2002) animals with ROSA26-lox-Stop-lox-b-Gal mouse line (Soriano, 1999) . GABA (250 mg/kg -Sigma) was administered by intraperitoneal injections of a solution prepared freshly once a week. Tamoxifen (TAM, Sigma) was dissolved in corn oil at a concentration of 20mg/ml and administered by gavage. To assess cell proliferation upon GABA addition, WT mice were treated with GABA and subsequently with BrdU for 10 days prior to examination. Cells that had incorporated BrdU (1mg/ml via drinking water) during DNA replication were detected by immunohistochemistry (Roche). Lastly, GABA was given to mice for 2 days prior to lentivirus administration. Ductal tree virus injections (Le-Ngn3KD or Le-(pMR')-eGFP) were then performed via the Papilla duodeni major as previously described (Xu et al., 2008) followed by intraperitoneal administration of GABA for 2 months.
Human Subjects
In accordance with the French authorities and with our Institutional Ethical Committee (« Comité d'Ethique du Centre Hospitialier Ré gional et Universitaire de Lille »), human islets, isolated from brain dead donors were used for research if islets were insufficient in number for clinical transplantation and only if scientific consent was obtained. Islets were transplanted under the kidney capsule of Swiss nu/nu mice (Charles River Laboratoires, Arbresle France) as described (Caiazzo et al., 2008) , following local ethical committee approval (CEEA2020111).
METHOD DETAILS Immunohistochemistry
Tissues were fixed in 4% PFA for 30min at 4 C, embedded in paraffin and 8 mm sections applied to slides. These sections were assayed as described previously (Collombat et al., 2003) . The primary antibodies used were the following: guinea pig polyclonal anti-insulin (1/500), anti-glucagon (1/500), mouse monoclonal anti-glucagon (1/500), anti-BrdU (1/40), anti-E-cadherin (1/200), rat anti-somatostatin (1/250), rabbit anti-Glut2 (1/500), anti-PC1/3 (1/500), anti-Nkx6.1 (1/3000), anti-Pdx1 (1/1000), anti-NeuroD1 (1/200), anti-Ngn3 (1/500), anti-b-galactosidase (1/10000), chicken anti-vimentin (1/5000), and goat anti-osteopontin (1/200). The secondary antibodies were used at a 1/1000 concentration. Pictures were processed using ZEISS Axioimager Z1 and LEICA DM(in [pH 7.4], 0.1M PB) overnight at 4 C, the samples were rapidly frozen in liquid nitrogen. Ultrathin (70 nm thick) cryosections were prepared with an ultracryomicrotome (Leica EMFCS, Austria) and mounted on formvar-coated nickel grids (Electron Microscopy Sciences, Fort Washington, PA, USA). Immunostainings were processed with an automated immunogold labeling system Leica EM IGL as following: the grids were incubated successively in PBS containing 50mM NH4Cl, PBS containing 1% BSA, PBS containing both anti-insulin and anti-glucagon primary antibodies diluted 1/1000 in 1% BSA for 1h, PBS containing 0.1% BSA, PBS containing 1% BSA and both 10 nm and 15 nm colloidal gold conjugated anti-guinea pig IgG and anti-mouse IgG, respectively, (BBInternational, Cardiff, UK), PBS containing 0.1% BSA for 5min, PBS for 5min twice. Lastly, the samples were fixed for 10 min with 1% glutaraldehyde, rinsed in distilled water and were contrasted with a mixture of 1.8% methylcellulose and 0.3% uranyl acetate on ice. After air-drying, sections were examined under a JEOL 1400 transmission electron microscope.
RNA Analysis
RNA isolation (RNAeasy, QIAGEN) and cDNA synthesis (Superscript choice system, Invitrogen) were performed according to the manufacturer's instructions. Quantitative RT-PCR was carried out using the QuantiTect SYBR Green RT-PCR Kit (QIAGEN) and validated primers (QIAGEN) according to the manufacturer's instructions. The PCR reactions and detection were performed on a light cycler (Roche) using GAPDH as internal controls for normalization purposes.
QUANTIFICATION AND STATISTICAL ANALYSIS

Cell Counts
Quantitative analyses were performed after immunostaining and photographing every 5 to 10 pancreatic section using an automatic mosaic acquisition system (Zeiss). Each photograph was converted to tif format (maintaining pixel/voxel size) and processed using FIJI (http://fiji.sc). For islet size quantification, particle analysis and water shedding filters were used with respect of DAPI + pixel counting. For hormone + cell counts, we used hormone + pixel counts with respect of DAPI + pixel numbers. For b-cell size, particle analysis and water shedding filters were applied to find islets and define these as regions of interest. A similar approach was used to find and count DAPI + nuclei within these regions.
Statistical Analysis
All values are depicted as mean ± SEM and considered significant if p < 0.05. Data were analyzed using Prism software (GraphPad) by first determining whether they followed a normal distribution using a D'Agostino-Pearson omnibus normality test. If not, an unpaired/nonparametric Mann-Whitney test was used. If yes, an unpaired t test (2 groups being compared) or an unpaired Anova test (several groups compared simultaneously) were used assuming Gaussian distribution. The F-test p values were also determined to check whether one should assume ''similar standard deviations'' or not. Figure S1 . Related to Figure 1 (A) Transcriptomics analyses of the pancreata from Glu-rtTA::TetO-Pax4 transgenic mice. Glu-rtTA::TetO-Pax4 animals were treated for 3 months with Dox or Saline prior to sacrifice for pancreatic islet isolation. Transcriptomics analyses were subsequently performed based on RNaseq. By focusing on genes displaying a significant 5-fold change in expression, our analyses outlined 48 genes comparing Dox-versus Saline-treated pancreata. Importantly, 22 of these appeared potentially linked to the GABA signaling pathway. (B) Arx transcript content quantification in a-TC1-6 cells treated with GABA. a-TC1-6 cells were treated with saline or increasing GABA concentrations for the indicated periods of time. Relative Arx transcript contents were quantified using quantitative RT-PCR. Note the progressive decrease in Arx expression (a hallmark of a-to-b-cell conversion) in all GABA treatment conditions, such decrease progressing with GABA exposure duration. *p < 0.05, **p < 0.01, ***p < 0.001; n R 3; data statistically analyzed by a one-way ANOVA by comparing all data points to matching control treatment durations, all data depicted as mean ± SEM. Figure S2 . Dose-Dependent Increase in Islet Number and Hormone-Expressing Cells in GABA-Treated Animals, Related to Figure 1 
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